Company Overview
Snapshot
Founded in January 2019 by Ziv Aviram, Yossi Ben Amram, and Hagai Greenspoon, Medicane Health operates with 11–50 employees. The company has secured $50 million in funding from private investors. In October 2022, Medicane Health announced the enrollment of the first patient in a Phase IIa clinical trial for its balanced T3:C3 oral medical cannabis oil, targeting behavioral and psychological symptoms of dementia (BPSD).
Business overview
Medicane Health is an international pharmaceutical company focused on the research, development, production, and marketing of cannabis-based medications. The company develops products through two regulatory pathways: medical cannabis using whole plant extractions and pharmaceutical products using isolated ingredients. Medicane Health serves European markets that support medical cannabis legislation, with operational subsidiaries in Israel and Portugal, and a commercial hub in Germany. The company aims to advance medical research in various therapeutic areas, exploring the connection between cannabis components and improving patient health, particularly for those whose needs are not met by traditional drug treatments. Medicane Health controls the seed-to-customer value chain to ensure the delivery of pharmaceutical-grade products.
Strategic signal
In April 2022, Medicane Health, in collaboration with Dr. Reddy's Laboratories, launched medical cannabis products in Germany. This strategic partnership, which began in 2021, positions Medicane Health to supply its EU-GMP-certified medical cannabis products to a major European pharmaceutical market. This launch signifies Medicane's entry into the pharmaceutical sector of Germany and reinforces Dr. Reddy's presence in the growing German medical cannabis market, indicating strong commercial validation and market expansion for Medicane Health.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant clinical development for Medicane Health?
- In October 2022, Medicane Health announced the enrollment of the first patient in a Phase IIa clinical trial. This trial is evaluating Medicane's balanced T3:C3 oral medical cannabis oil for the symptom relief of Behavioral and Psychological Symptoms of Dementia (BPSD).
- What strategic partnership did Medicane Health form in the German market?
- In April 2022, Medicane Health and Dr. Reddy's Laboratories launched medical cannabis products in Germany. This collaboration involves Medicane supplying products from its EU-GMP-certified facilities in Portugal to Dr. Reddy's.
- What regulatory milestone did Medicane Health achieve for its manufacturing facility?
- In February 2022, Medicane Health received an EU GMP License for its manufacturing plant located in Portugal. This license is crucial for producing pharmaceutical-grade medical cannabis products for the European market.
- What digital platform did Medicane Health launch for medical cannabis patients?
- In July 2021, Medicane Health launched EcoCaNN, the first social media platform for medical cannabis patients in Israel. The app, based on Belong.life's technology, allows patients to consult with professionals and access information.
- What was Medicane Health's funding status in early 2021?
- In January 2021, Medicane Health had received $50 million in investments from private investors, including co-founder.